# DOD Amyotrophic Lateral Sclerosis, Clinical Biomarker Development Award

Source: https://welltoldgrants.com/grants/ht9425-23-alsrp-cbda-dod-amyotrophic-lateral-sclerosis-clinical-biomarker/  
Official notice: https://www.grants.gov/search-results-detail/345881

> Defense Health Agency Contracting Activity - DHACA offered grants to any type of organization. It expected to make about 10 awards worth $7.2 million in total. Applications closed on July 13, 2023.

| Field | Value |
|---|---|
| Opportunity number | HT9425-23-ALSRP-CBDA |
| Agency | Defense Health Agency Contracting Activity - DHACA |
| Status | Forecast |
| Deadline | July 13, 2023 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 10 |
| Total funding | $7.2 million |
| Cost sharing | not required |
| Assistance Listings | 12.420 |

## Who can apply

- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

## What the grant funds

The intent of the FY23 ALSRP Clinical Biomarker Development Award is to support the development of biomarkers to enrich clinical trials in Amyotrophic Lateral Sclerosis (ALS). Biomarker development projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. A description of the biomarker category and intended context of use (COU) in ALS therapeutic development, including regulatory considerations for use in ALS clinical trials or clinical practice, is an important component. Examples of studies appropriate for submission to the FY23 ALSRP Clinical Biomarker Development Award include, but are not limited to: Using patient-based resources to link biosamples to rigorous molecular data. Collecting and analyzing biospecimens as a companion to an anticipated/ongoing clinical trial. Correlation of clinical trial-related data (e.g., biosample analysis, imaging, or epidemiological data) with clinical outcomes or responses to therapies. Strategies to better measure disease progression, including the development or use of digital biomarkers.

## Questions people ask

### Is HT9425-23-ALSRP-CBDA still open?

No. It closed on July 13, 2023. A newer notice is open: HT942526BCRPCREA2, closes November 18, 2026 (11 days left).

### Who can apply for DOD Amyotrophic Lateral Sclerosis, Clinical Biomarker Development Award?

Defense Health Agency Contracting Activity - DHACA accepted applications from any type of organization.

### What is the deadline for DOD Amyotrophic Lateral Sclerosis, Clinical Biomarker Development Award?

Closed July 13, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

About $7.2 million in total across about 10 awards.

### Who has won Military Medical Research and Development grants before?

The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Univeristy of Texas M.D. Anderson Cancer Center, The Johns Hopkins University. The program made 5,470 awards worth $6.9 billion in that time.